A Primer on Chimera Associated Receptor T-Cells

Overview

Journal Mo Med

Specialty General Medicine

Date 2021 Oct 18

PMID 34658441

Authors

Sumalatha Muthineni

Katelyn Zink

Suman Kambhampati

Affiliations

Soon will be listed here.

Abstract

Cancer continues to be one of the leading causes of death. Although survival rates have improved with current treatments for hematological malignancies, relapsed and refractory cases have poor prognosis. Immunotherapy against cancer cells offer new hope for curative response in these patients. Of those, Chimeric Antigen Receptor (CAR) T-cells are emerging as promising therapy for hematological malignancies, where T-lymphocytes are genetically engineered with CAR to recognize and eliminate specific tumor cells. The efficacy of CAR T-cell therapy is also being studied in solid tumors. In this review, the basic principles of CAR T-cell therapy are discussed.

References

Curran K, Pegram H, Brentjens R . Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med. 2012; 14(6):405-15. PMC: 4697438. DOI: 10.1002/jgm.2604. View

Sadelain M . CAR therapy: the CD19 paradigm. J Clin Invest. 2015; 125(9):3392-400. PMC: 4588281. DOI: 10.1172/JCI80010. View

Ritchie D, Neeson P, Khot A, Peinert S, Tai T, Tainton K . Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013; 21(11):2122-9. PMC: 3831035. DOI: 10.1038/mt.2013.154. View

Tang X, Sun Y, Zhang A, Hu G, Cao W, Wang D . Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol. BMJ Open. 2017; 6(12):e013904. PMC: 5223707. DOI: 10.1136/bmjopen-2016-013904. View

Skorka K, Ostapinska K, Malesa A, Giannopoulos K . The Application of CAR-T Cells in Haematological Malignancies. Arch Immunol Ther Exp (Warsz). 2020; 68(6):34. PMC: 7647970. DOI: 10.1007/s00005-020-00599-x. View

Masopust D, Schenkel J . The integration of T cell migration, differentiation and function. Nat Rev Immunol. 2013; 13(5):309-20. DOI: 10.1038/nri3442. View

Yu S, Li A, Liu Q, Li T, Yuan X, Han X . Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol. 2017; 10(1):78. PMC: 5372296. DOI: 10.1186/s13045-017-0444-9. View

Wang Z, Guo Y, Han W . Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. Protein Cell. 2017; 8(12):896-925. PMC: 5712290. DOI: 10.1007/s13238-017-0400-z. View

June C, OConnor R, Kawalekar O, Ghassemi S, Milone M . CAR T cell immunotherapy for human cancer. Science. 2018; 359(6382):1361-1365. DOI: 10.1126/science.aar6711. View

10.

Heyman B, Yang Y . New developments in immunotherapy for lymphoma. Cancer Biol Med. 2018; 15(3):189-209. PMC: 6121050. DOI: 10.20892/j.issn.2095-3941.2018.0037. View

11.

Ali N . Chimeric antigen T cell receptor treatment in hematological malignancies. Blood Res. 2019; 54(2):81-83. PMC: 6614098. DOI: 10.5045/br.2019.54.2.81. View

12.

Li D, Li X, Zhou W, Huang Y, Liang X, Jiang L . Genetically engineered T cells for cancer immunotherapy. Signal Transduct Target Ther. 2019; 4:35. PMC: 6799837. DOI: 10.1038/s41392-019-0070-9. View

13.

Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S . Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2018; 120(1):26-37. PMC: 6325111. DOI: 10.1038/s41416-018-0325-1. View

14.

Sadelain M, Riviere I, Riddell S . Therapeutic T cell engineering. Nature. 2017; 545(7655):423-431. PMC: 5632949. DOI: 10.1038/nature22395. View

15.

Han D, Xu Z, Zhuang Y, Ye Z, Qian Q . Current Progress in CAR-T Cell Therapy for Hematological Malignancies. J Cancer. 2021; 12(2):326-334. PMC: 7738987. DOI: 10.7150/jca.48976. View

16.

Neelapu S . Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019; 37 Suppl 1:48-52. DOI: 10.1002/hon.2595. View

17.

Beyar-Katz O, Gill S . Advances in chimeric antigen receptor T cells. Curr Opin Hematol. 2020; 27(6):368-377. DOI: 10.1097/MOH.0000000000000614. View

18.

Ruhlmann C, Iversen T, Okera M, Muhic A, Kristensen G, Feyer P . Multinational study exploring patients' perceptions of side-effects induced by chemo-radiotherapy. Radiother Oncol. 2015; 117(2):333-7. DOI: 10.1016/j.radonc.2015.09.014. View

19.

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

20.

Song M, Park B, Uhm J . Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies. Int J Mol Sci. 2019; 20(20). PMC: 6834308. DOI: 10.3390/ijms20205010. View